AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15987289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 12859036 — intervention group
Group type: EXPERIMENTAL
Intervention: Douching product
Number of subjects: 1827
Study 12859036 — intervention group
Group type: EXPERIMENTAL
Intervention: Douching product (frequent use)
Number of subjects: 1827
Study 12859036 — intervention group
Group type: COMPARATOR
Intervention: Soft cloth towelette
Number of subjects: 1827
Study 10855121 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic esophageal stents
Number of subjects: 63
Study 8522380 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ceftazidime i.v. t.d.s.
Number of subjects: 127
Study 8522380 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg ceftazidime i.v. t.d.s.
Number of subjects: 127
Study 2042997 — intervention group
Group type: EXPERIMENTAL
Intervention: HMM II method
Number of subjects: 45
Study 2042997 — intervention group
Group type: COMPARATOR
Intervention: Bergqvist method
Number of subjects: 45
Study 6111438 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of beta-receptor blocker and diuretic (10 mg pindolol and 5 mg clopamide daily)
Number of subjects: 15
Study 6111438 — intervention group
Group type: COMPARATOR
Intervention: Combination of beta-receptor blocker, diuretic and sodium-preserving diuretic (10 mg timolol, 25 mg hydrochlorothiazide and 2.5 mg amiloride)
Number of subjects: 15
Study 28939629 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolongation of adalimumab dosing interval to once every 3 weeks
Number of subjects: 55
Study 28939629 — intervention group
Group type: COMPARATOR
Intervention: Continuation of adalimumab dosing interval every other week
Number of subjects: 55
Study 28939629 — intervention group
Group type: COMPARATOR
Intervention: Prolongation group vs continuation group
Number of subjects: 55
Study 26201083 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment
Number of subjects: 121
Study 26201083 — intervention group
Group type: COMPARATOR
Intervention: Adolescent-focused therapy
Number of subjects: 121
Study 26201083 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hostility
Number of subjects: 121
Study 26201083 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal criticism
Number of subjects: 121
Study 25728105 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis chewing gum
Number of subjects: 30
Study 25728105 — intervention group
Group type: COMPARATOR
Intervention: Xylitol chewing gum
Number of subjects: 30
Study 22546131 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine (LB) 66, 199, or 266 mg
Number of subjects: 100
Study 22546131 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 266 mg
Number of subjects: 100
Study 22546131 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine HCl 75 mg
Number of subjects: 100
Study 20133204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-dose dexamethasone
Number of subjects: 40
Study 20133204 — intervention group
Group type: COMPARATOR
Intervention: Standard oral prednisolone
Number of subjects: 40
Study 17397425 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial falls intervention (two in-home visits, recommendations, referrals, 11 monthly calls, balance exercise plan)
Number of subjects: 349
Study 17397425 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial falls intervention
Number of subjects: 349
Study 17397425 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial falls intervention (for subjects with MMSE score of 27 or less)
Number of subjects: 349
Study 17397425 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial falls intervention (for subjects with MMSE score of 27 or less and living with someone)
Number of subjects: 349
Study 17397425 — intervention group
Group type: COMPARATOR
Intervention: Control group (home safety assessment)
Number of subjects: 349
Study 15736248 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg t.i.d. for 6 months
Number of subjects: 933
Study 15736248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 933
Study 11896096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU) chemotherapy at doses of 370 to 450 mg/m² for 5 consecutive days
Number of subjects: 1093
Study 11896096 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (5-FU) chemotherapy
Number of subjects: 1093
Study 9579771 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg
Number of subjects: 200
Study 9579771 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 200
Study 7659440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (KET) 60 mg before induction (PRE group)
Number of subjects: 60
Study 7659440 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (CONT group)
Number of subjects: 60
Study 7659440 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline followed by intravenous ketorolac (KET) 60 mg (POST group)
Number of subjects: 60
Study 7659440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (KET) 60 mg (PRE group)
Number of subjects: 60
Study 2683424 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-rich Cohn-IV-1 fractions infusion (100 ml every 2 weeks)
Number of subjects: 14
Study 2683424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine and a choleretic drug (permanent medication)
Number of subjects: 14
Study 2683424 — intervention group
Group type: COMPARATOR
Intervention: Control group (normolipaemic smokers)
Number of subjects: 14
Study 30367877 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge FNA (EchoTip Ultra)
Number of subjects: 608
Study 30367877 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge FNB (ProCore)
Number of subjects: 608
Study 25398072 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-specific experiential avoidance
Number of subjects: 465
Study 25398072 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait worry
Number of subjects: 465
Study 25046539 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISO: 0.05 μg/kg per minute)
Number of subjects: 9
Study 25046539 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 9
Study 21834938 — intervention group
Group type: EXPERIMENTAL
Intervention: PP 1420 (2, 4, and 8 mg)
Number of subjects: 12
Study 21834938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20507969 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) - 4 weeks, 30 breaths twice daily at approximately 50% of maximum inspiratory pressure (MIP)
Number of subjects: 16
Study 20507969 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment - 4 weeks, 60 breaths once daily at approximately 15% of MIP
Number of subjects: 16
Study 18699898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg.kg(‐1) administered at 4 min before rocuronium
Number of subjects: 75
Study 18699898 — intervention group
Group type: COMPARATOR
Intervention: Saline administered at 4 min before rocuronium (Control)
Number of subjects: 75
Study 18699898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg.kg(‐1) administered at 30 s before rocuronium (Late)
Number of subjects: 75
Study 16192841 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/day
Number of subjects: 29
Study 16192841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12787453 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat plane interocclusal appliance (maxillary splint)
Number of subjects: 20
Study 9129896 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 1.25 mg
Number of subjects: 40
Study 9129896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline intravenously)
Number of subjects: 40
Study 1901187 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms vaccine
Number of subjects: 25
Study 1901187 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms vaccine
Number of subjects: 25
Study 1901187 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms vaccine
Number of subjects: 25
Study 7092002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline, 500 mg by mouth every 6 hours for 1 week
Number of subjects: 40
Study 7092002 — intervention group
Group type: COMPARATOR
Intervention: Placebo by mouth every 6 hours for 1 week
Number of subjects: 40
Study 31633625 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-finger (TF) method
Number of subjects: 42
Study 31633625 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb (TT) method
Number of subjects: 42
Study 30798020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory assessment methods for treatment adherence and substance use data collection
Number of subjects: 0
Study 30798020 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility criteria verification, treatment adherence monitoring, and remote assessment of substance use and biomarkers
Number of subjects: 0
Study 27835613 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-containing regimen (tenofovir + lamivudine/emtricitabine + efavirenz)
Number of subjects: 59
Study 27835613 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir-sparing regimen (zidovudine + lamivudine/emtricitabine + efavirenz)
Number of subjects: 59
Study 27835613 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir-sparing regimen
Number of subjects: 59
Study 27835613 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-containing regimen
Number of subjects: 59
Study 26704144 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses with positive spherical aberration (+SA)
Number of subjects: 127
Study 26704144 — intervention group
Group type: COMPARATOR
Intervention: Control (spherical design) soft contact lenses
Number of subjects: 127
Study 24560581 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (breath alcohol concentration of .6 g/kg)
Number of subjects: 50
Study 24560581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24560581 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 50
Study 22038192 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis with corticosteroid (PCS)
Number of subjects: 47
Study 22038192 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis with non-steroid anti-inflammatory drug (PNSAI)
Number of subjects: 47
Study 22038192 — intervention group
Group type: COMPARATOR
Intervention: Wrist splinting alone
Number of subjects: 47
Study 19106767 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 1-4 mg doses
Number of subjects: 6
Study 19106767 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 6
Study 19106767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 17049767 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer group
Number of subjects: 2492
Study 17049767 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2492
Study 15147428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 124
Study 15147428 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 124
Study 11642473 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 19
Study 9541371 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feedback
Number of subjects: 68
Study 9541371 — intervention group
Group type: COMPARATOR
Intervention: Written feedback
Number of subjects: 68
Study 9541371 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feedback (University 1)
Number of subjects: 68
Study 9541371 — intervention group
Group type: COMPARATOR
Intervention: Written feedback (University 1)
Number of subjects: 68
Study 9541371 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feedback (University 2)
Number of subjects: 68
Study 9541371 — intervention group
Group type: COMPARATOR
Intervention: Written feedback (University 2)
Number of subjects: 68
Study 7759715 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 96
Study 7759715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 2301864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceravital
Number of subjects: 112
Study 2301864 — intervention group
Group type: COMPARATOR
Intervention: Plastipore
Number of subjects: 112
Study 371887 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (9 units total, 1 unit = 5 x 10(8) lymphocytes)
Number of subjects: 14
Study 371887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30708350 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum tDCS (20 min; 1 mA; anode [C3], cathode [Fp2])
Number of subjects: 10
Study 30708350 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study 29098244 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sevoflurane for 2 h
Number of subjects: 4
Study 29098244 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 h exposure)
Number of subjects: 4
Study 29098244 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sevoflurane for 0.5 h
Number of subjects: 4
Study 29098244 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sevoflurane for 1 h
Number of subjects: 4
Study 25935771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose tolerance test in chronic kidney disease patients
Number of subjects: 75
Study 25935771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose tolerance test in metabolic syndrome patients
Number of subjects: 75
Study 25935771 — intervention group
Group type: COMPARATOR
Intervention: Fructose tolerance test in healthy controls
Number of subjects: 75
Study 24630598 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative assessment of pain intensity with active flexion and extension
Number of subjects: 215
Study 24630598 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative simple knee range-of-motion test
Number of subjects: 215
Study 22617128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 4 mg every 3 weeks for 1 year
Number of subjects: 119
Study 22617128 — intervention group
Group type: COMPARATOR
Intervention: No zoledronic acid (control)
Number of subjects: 119
Study 20059492 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin applied to one side of nasolabial folds
Number of subjects: 144
Study 20059492 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied as control to the other side of nasolabial folds
Number of subjects: 144
Study 17805038 — intervention group
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase (ASP) substituted at the same dose and schedule due to allergic reaction to E. coli ASP
Number of subjects: 540
Study 17805038 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular E. coli ASP (6000 U/m2x6) followed by intensive weekly intramuscular E. coli ASP (25,000 U/m2/wkx24)
Number of subjects: 540
Study 12949013 — intervention group
Group type: EXPERIMENTAL
Intervention: Underfed (UF) group
Number of subjects: 19
Study 12949013 — intervention group
Group type: COMPARATOR
Intervention: Overfed (OF) group
Number of subjects: 19
Study 11833245 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPAP 15 minutes, four times per day for three days
Number of subjects: 57
Study 11833245 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPAP 30 minutes, four times per day for three days
Number of subjects: 57
Study 11833245 — intervention group
Group type: COMPARATOR
Intervention: Traditional physiotherapy only (control group)
Number of subjects: 57
Study 9735610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 107
Study 9735610 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic-behavioral family therapy
Number of subjects: 107
Study 9735610 — intervention group
Group type: COMPARATOR
Intervention: Nondirective supportive therapy
Number of subjects: 107
Study 9735610 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 107
Study 10621922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium-free alginate
Number of subjects: 90
Study 10621922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10621922 — intervention group
Group type: COMPARATOR
Intervention: Aluminium-free alginate and Placebo
Number of subjects: 90
Study 2199148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nasal CPAP) for 12 hours after 18 hours of PEEP on the ventilator
Number of subjects: 0
Study 2199148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nasal CPAP)
Number of subjects: 0
Study 2199148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 0
Study 2199148 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 343403 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone and isoniazide for six and 12 months
Number of subjects: 280
Study 343403 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 280
Study 30580203 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-only treatment program for caffeine cessation and reduction over a period of 6 weeks; no counseling or additional support.
Number of subjects: 0
Study 30580203 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group (manual-only treatment).
Number of subjects: 0
Study 30580203 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group (treatment delayed by 7 weeks).
Number of subjects: 0
Study 27920249 — intervention group
Group type: EXPERIMENTAL
Intervention: 5S (Sort, Set, Shine, Standardize, Sustain) approach as a CQI method implemented at outpatient departments over 12 months
Number of subjects: 3292
Study 27920249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 3292
Study 26115748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine triphosphate (ATP) administered after successful PVI to reveal dormant conduction (DC) sites.
Number of subjects: 91
Study 26115748 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (RC sites differed from DC sites)
Number of subjects: 91
Study 26115748 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (RC sites identical to DC sites)
Number of subjects: 91
Study 26115748 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (RC sites involved both DC and other sites)
Number of subjects: 91
Study 23809197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention (Brain Fitness)
Number of subjects: 34
Study 23809197 — intervention group
Group type: COMPARATOR
Intervention: Health education active control intervention
Number of subjects: 34
Study 21997315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (10-week treatment)
Number of subjects: 76
Study 21997315 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10-week treatment)
Number of subjects: 76
Study 18647427 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Number of subjects: 300
Study 18647427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary Conley
Number of subjects: 300
Study 18647427 — intervention group
Group type: EXPERIMENTAL
Intervention: Atkins
Number of subjects: 300
Study 18647427 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 300
Study 16959685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined systemic and local Pycnogenol treatment
Number of subjects: 30
Study 16959685 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Pycnogenol only
Number of subjects: 30
Study 16959685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Pycnogenol only
Number of subjects: 30
Study 16959685 — intervention group
Group type: COMPARATOR
Intervention: Medications only (control group)
Number of subjects: 30
Study 14976608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmidomycin-clindamycin (30 and 5 mg/kg body weight every 12 h for 5 days)
Number of subjects: 36
Study 14976608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmidomycin alone (30 mg/kg body weight every 12 h for 5 days)
Number of subjects: 36
Study 14976608 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin alone (5 mg/kg body weight every 12 h for 5 days)
Number of subjects: 36
Study 11693335 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MU alpha-interferon three times a week for 6 months
Number of subjects: 30
Study 11693335 — intervention group
Group type: COMPARATOR
Intervention: 6 MU alpha-interferon three times a week for 6 months
Number of subjects: 30
Study 9469525 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10 mg subcutaneous before surgery and 30 ml saline infiltrated into the wound at skin incision)
Number of subjects: 29
Study 9469525 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline (1 ml into an arm before surgery) and Morphine (10 mg in 30 ml saline into the wound at skin incision)
Number of subjects: 29
Study 9469525 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of i.v. morphine
Number of subjects: 29
Study 9469525 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 29
Study 7609496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0
Study 7609496 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine SR
Number of subjects: 0
Study 2907519 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40, 80 mg twice daily)
Number of subjects: 33
Study 2907519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20, 40 mg twice daily)
Number of subjects: 33
Study 2907519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Propranolol added to Ketanserin)
Number of subjects: 33
Study 2907519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Ketanserin added to Propranolol)
Number of subjects: 33
Study 2907519 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 33
Study 2907519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 33
Study 31854481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Parents were responsible for booking consultations and contacting the clinic as needed.
Number of subjects: 139